A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

NCT03085173 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)
Relapsed
Refractory

Interventions

BIOLOGICAL: EGFRt/19-28z/4-1BBL CAR T cells

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]